Project status: Closed
This project aimed to explore patients’ perspectives on new and existing treatments for myeloma.
Myeloma patients may undergo many different types of treatment over the course of their cancer. There is already a high burden on patients due to the myeloma diagnosis, complications, and side-effects of treatment. We need evidence about how patients feel about how treatments are administered (i.e. intravenous, subcutaneous or oral routes of administration) and where (i.e. at home, in the community, or in a hospital). This evidence is critical to informed decision-making and to drive change in industry and regulatory institutions as they consider how drugs should be produced and administered. Understanding how patients feel about how, when and where they get their myeloma treatment is key to efforts to improve patient quality of life and minimise the burden of treatments.
The project involved an online survey of patients and informal family carers across Europe. Read about the results in our report and further publications below.
Publications and outputs:
Research summary: How do European myeloma patients feel about how when and where they get their treatment?
Original research article in Frontiers in Hematology:
Duncan EM, ten Seldam S, Leleu X, Loening-Martens D, Pawlyn C, Wollenschneider S, Joyner K and Morgan K (2026) Myeloma patients’ attitudes and perceived burden of treatment
Administration routes and locations: insights from a pan-European survey
We would like to sincerely thank all the participants who contributed their time to the survey and all MPE’s member organisations who kindly assisted with recruitment. In particular, grateful thanks go to Leukämiehilfe Rhein-Main E. V., AMM-Online, Hematon, The Norwegian Blood Cancer Association, Assoiação Portuguesa Contra A Leucemia, Fundacja Carita im. Wiesławy Adamiec, Multiple Myeloma Ireland, Association Française des Malades du Myélome Multiple (AF3M), and AMEN Israel.
Thank you to Pfizer, Sanofi and Takeda for funding this research project. Funders had no role in the design, collection, analysis or interpretation of data.